Fluticasone propionate nasal spray versus montelukast in patients with asthma and seasonal allergic rhinitis receiving fluticasone propionate/salmeterol

Phase 4, randomised, triple-blind trial of fluticasone propionate, salmeterol + fluticasone and montelukast in asthma and seasonal allergic rhinitis (SAR) (4 arms), sponsored by GSK. Primary endpoints: Mean change from baseline in morning peak expiratory flow at endpoint: fluticasone propionate/salmeterol versus montelukast and Mean change from baseline in morning peak expiratory flow at endpoint: fluticasone propionate/salmeterol versus fluticasone propionate/salmeterol plus montelukast. Started Feb 2007; status: completed.